Intervention Review

You have free access to this content

Corticosteroids for viral myocarditis

  1. Huai Sheng Chen1,*,
  2. Wei Wang2,
  3. Sheng Nan Wu3,
  4. Jian Ping Liu4

Editorial Group: Cochrane Heart Group

Published Online: 18 OCT 2013

Assessed as up-to-date: 25 JUL 2012

DOI: 10.1002/14651858.CD004471.pub3


How to Cite

Chen HS, Wang W, Wu SN, Liu JP. Corticosteroids for viral myocarditis. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD004471. DOI: 10.1002/14651858.CD004471.pub3.

Author Information

  1. 1

    The Second Affiliated Hospital of Ji Nan University, Intensive Care Unit, Shenzhen People's Hospital, Shenzhen City, Guangdong, China

  2. 2

    Shenzhen People's Hospital, Endocrinology, Shenzhen City, China

  3. 3

    Shenzhen People's Hospital, The Second Affiliated Hospital of Ji Nan University, Intensive Care Unit, Shenzhen City, GuangDong Province, China

  4. 4

    Beijing University of Chinese Medicine, Centre for Evidence-Based Chinese Medicine, Beijing, China

*Huai Sheng Chen, Intensive Care Unit, Shenzhen People's Hospital, The Second Affiliated Hospital of Ji Nan University, 1017 Dong Men Bei Lu, Luo Hu District, Shenzhen City, Guangdong, 518020, China. sunshinic@hotmail.com.

Publication History

  1. Publication Status: New search for studies and content updated (conclusions changed)
  2. Published Online: 18 OCT 2013

SEARCH

[Figure 1]
Figure 1. Flow diagram
[Figure 2]
Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 3]
Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Mortality, Outcome 1 Mortality.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Mortality, Outcome 2 Clinical endpoint (death and heart transplantation rates).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Mortality, Outcome 3 Mortality in children.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Myocardial function, Outcome 1 NYHA class at follow-up.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Myocardial function, Outcome 2 LVEF at 1 - 3 months follow-up.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Myocardial function, Outcome 3 LVEF at 1 - 3 months in children.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Myocardial function, Outcome 4 LVEF at long-term follow-up.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Myocardial function, Outcome 5 LVEDD at the end of observation.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Myocardial function, Outcome 6 LVESD at one-year follow-up.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Myocardial enzyme, Outcome 1 Level of Creatine Phosphokinase.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Myocardial enzyme, Outcome 2 Level of Creatine Phosphokinase-MB.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Myocardial enzyme, Outcome 3 alpha-HBDH.